Home › Non-Small Cell Lung Cancer › California
Non-Small Cell Lung Cancer clinical trials in California
210 studies for Non-Small Cell Lung Cancer are looking for participants at sites in California.
Cities in California
- Los Angeles92 studies
- San Diego49 studies
- Santa Monica45 studies
- San Francisco37 studies
- Baldwin Park36 studies
- Irvine30 studies
- Sacramento29 studies
- Orange28 studies
- Mountain View26 studies
- Santa Rosa16 studies
- Fullerton14 studies
- Concord13 studies
- Torrance12 studies
- Huntington Beach12 studies
- Newport Beach12 studies
- Roseville11 studies
- Long Beach11 studies
- Vallejo10 studies
- Anaheim9 studies
- San Bernardino9 studies
- Burbank8 studies
- Glendale8 studies
- Westminster7 studies
- Richmond7 studies
- Modesto7 studies
- San Jose7 studies
- Fresno7 studies
- Santa Barbara6 studies
- Berkeley6 studies
- Stockton6 studies
- Fremont6 studies
- Oakland6 studies
- Sunnyvale5 studies
- Santa Clara5 studies
- San Leandro5 studies
- Daly City5 studies
- Santa Maria4 studies
- Lancaster4 studies
- Oxnard4 studies
- Riverside4 studies
- San Mateo4 studies
- Alhambra3 studies
- Mission Viejo3 studies
- Upland3 studies
- San Marcos3 studies
- Fontana3 studies
- Carson3 studies
- Ontario3 studies
- Bellflower3 studies
- Yuba City3 studies
- Clovis3 studies
- Pleasanton3 studies
- Salinas3 studies
- Redwood City3 studies
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Sansum Clinic, Santa Barbara
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Nov 13, 2026 · NCT05920356A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- START Los Angeles, Los Angeles
- UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07488676A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- START LA, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07659782A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- UCLA Hematology Oncology - Main Site, Los Angeles
- Stanford Cancer Institute, Stanford
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07111520Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building, Irvine
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07100080A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Beverly Hills Cancer Center ( Site 0142), Beverly Hills
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07190248This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center, Fullerton
- Providence St. Jude Medical Center, Fullerton
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06758401Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Tower Cancer Research Foundation, Beverly Hills
- Kaiser Permanente Dublin, Dublin
- Kaiser Permanente-Fremont, Fremont
- and 20 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06498635BostonGene and Exigent Genomic INsight Study
- Stockton Hematology Oncology Medical Group, Stockton
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06272864Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Kaiser Permanente-Anaheim, Anaheim
- Kaiser Permanente-Deer Valley Medical Center, Antioch
- Sutter Auburn Faith Hospital, Auburn
- and 56 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04267848A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- CBCC Global Research, Inc. ( Site 0123), Bakersfield
- Beverly Hills Cancer Center ( Site 0116), Beverly Hills
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06345729Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Clinical Research Advisors, LLC, Beverly Hills
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06472245Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- City of Hope-Duarte-56419, Duarte
- Valkyrie Clinical Trials, Los Angeles
- University of California Irvine, Orange
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04886804A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- City of Hope - Duarte Cancer Center, Duarte
- UCLA Health Bowyer Oncology Center, Los Angeles
- UCSF Helen Diller Medical Center at Parnassus Heights - Neurology, San Francisco
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06914128A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Cedars-Sinai Medical Center, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Beverly Hills Cancer Center ( Site 0070), Beverly Hills
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0033), Los Angeles
- Hoag Memorial Hospital Presbyterian ( Site 0096), Newport Beach
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06312137A Study of DS-3939a in Participants With Solid Tumors
- UCLA Health, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07739966Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Ellison Institute, Los Angeles
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT04557449A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- City of Hope Comprehensive Cancer Center, Duarte
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07503808Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Local Institution - 0212, Beverly Hills
- Local Institution - 0504, Fullerton
- Local Institution - 0357, La Jolla
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07680790Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Duarte
- Research Site, Irvine
- Research Site, La Jolla
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07291037LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- St. Jude Herritage Medical Group, Fullerton
- Hoag Family Cancer Institute - Hoag Memorial Hospital, Newport Beach
- Sutter Institute for Medical Research, Sacramento
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06216301A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Providence St. Jude Medical Center ( Site 0106), Fullerton
- VA Long Beach Healthcare System ( Site 0199), Long Beach
- USC Norris Comprehensive Cancer Center ( Site 0205), Los Angeles
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06623422A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- UC Davis Comprehensive Cancer Center ( Site 3204), Sacramento
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07513376A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Community Cancer Institute (CCI), Clovis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07541170A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento
- UCLA Hematology/Oncology - Santa Monica, Santa Monica
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06561386A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
- Oncura Health d.b.a.Los Angeles Cancer Network, Glendale
- UCLA Health - Santa Monica Cancer Care, Los Angeles
- UCSF Health - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07566052Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- UC Irvine Health, Orange
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT06881784A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Providence Medical Group, Santa Rosa
RecruitingPhase 1
Ages 18 to 99 · All sexes · Updated Nov 6, 2026 · NCT06983743Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Oncura Health, Glendale
- UC San Diego Health - Moores Cancer Center, La Jolla
- California Research Institute, Los Angeles
- and 4 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04198766A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- UCLA Hematology/Oncology - Alhambra, Alhambra
- UCLA Hematology/Oncology - Atascadero, Atascadero
- Alta Bates Summit Medical Center Comprehensive Cancer Center, Berkeley
- and 35 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07144280A 2-part Phase 1/2 Open-label Trial on ODM-212
- Valkyrie Clinical Trials, Los Angeles
- UC Irvine Health, Orange
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07563738A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- City of Hope National Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
- Administrative Address: UCLA Hematology/Oncology, Los Angeles
- and 3 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07090499Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Kaiser Permanente-Anaheim, Anaheim
- Kaiser Permanente-Baldwin Park, Baldwin Park
- Kaiser Permanente-Bellflower, Bellflower
- and 15 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07388524A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Community Cancer Institute (CCI), Clovis
- Marin Cancer Care Inc, Greenbrae
- UCI Health-CIACC, Irvine
- and 6 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06793215A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- City of Hope National Medical Center, Duarte
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06465069Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- City of Hope, Duarte, Duarte
- City of Hope Lennar, Irvine
- UCLA Hematology/Oncology - Santa Monica, Los Angeles
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06890598A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Stanford Cancer Institute, Palo Alto
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06150664A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- The Regents of the University of California - Irvine, CA Campus, Irvine
- UC San Diego Moores Cancer Center, La Jolla
- Cedars-Sinai Cancer at Cedars Sinai Medical Center, Los Angeles
- and 2 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06706076Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of California Los Angeles Medical Center, Los Angeles
- University of California, San Diego; Moores Cancer Center, San Diego
- USOR Sansum Clinic, Santa Barbara
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.